Fig. 4: WT to cell death competition assays in cerebral organoids.
From: Cerebral organoids display dynamic clonal growth and tunable tissue replenishment
a, Scheme of experimental setup of chimeric organoid formation and readout containing WT cells and GFP-labelled puromycin-resistant cells of different mixtures. b,c, GFP-puromycin-resistant cell percentages (b) and overall cell numbers (c) of chimeric organoids of the indicated composition with and without puromycin treatments over time (n = 6 organoids as biological replicates from 2 differentiation experiments at each time point for each ± puromycin treatment). Data points in b represent mean ± s.e.m.; area in c represents relative organoid size by cell number. d, Whole organoid lineage tracing of WT (90%) and GFP-puromycin-resistant (10%) cells. Lineage size distribution in conditions indicated on the top (n = individual lineages from 3 biological replicates from 1 experiment for each ± puromycin treatment). e,f, Optimal transport comparison of lineage populations of WT and GFP-puromycin-resistant cells in chimeric organoids containing WT:GFP-puro in 80:20 (e) and 90:10 (f) ratios. Left: GFP-puromycin-resistant to WT comparison in the absence of puromycin. Middle: GFP-puromycin-resistant to WT comparison in the presence of puromycin from day 11 onwards. Right: GFP-puromycin-resistant cells in chimeric organoids treated with puromycin in comparison to the same GFP-puromycin-resistant population in chimeric untreated organoids. Thickness of curves indicates number of lineages of certain sizes, dashed line indicates mean (n = individual lineages from 3 biological replicates from 1 experiment at each time point ± puromycin treatment).
